Research programme: mGlu3 receptor allosteric modulators - Addex Therapeutics/Pierre Fabre Pharmaceuticals
Latest Information Update: 26 Apr 2016
At a glance
- Originator Addex Therapeutics
- Developer Addex Therapeutics; Pierre Fabre
- Mechanism of Action Metabotropic glutamate receptor 3 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 08 Sep 2015 Early research in CNS disorders in Switzerland and France (unspecified route)